Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9870MR)

This product GTTS-WQ9870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13442MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ15293MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ13989MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15822MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ2947MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ11348MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ11575MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ2432MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW